Our mission is to bridge the

cancer care gap

by advancing revolutionary technologies

Singapore’s Ministry of Health approves KYAN’s clinical laboratory license to provide the Optim.AI™ functional precision medicine test

KYAN Technologies, a pioneering leader in the field of functional precision medicine for oncology. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise.

  • Optim.AI™
  • Personalized Cancer Solution
  • Small Data AI
  • Functional Precision Medicine
  • Biopharma
  • Optim.AI™
  • Personalized Cancer Solution
  • Small Data AI
  • Functional Precision Medicine
  • Biopharma

Our Technology

Our revolutionary technology is a phenotypic response system that efficiently identifies safe and effective drug -dose combination therapies

Small Data AI

Efficiently solves large and dynamic complex systems through a minimum number of tests

Experimental Biology

Prospective experiments that identify the optimal phenotypic response surface across different biological models

Clinical Decision Support

Our ex vivo analytic platform, Optim.AI™, empowers oncologists to better guide treatment for patients with truly personalized results

How we are different from standard care and other options

Standard Therapy

SAME treatment for all patients and most will fail, requiring multiple lines of treatment

Precision Medicine

SMALL chance that patients have identifiable biomarkers matched with therapy (est. < 10%)

Drug Sensitivity

LIMITED results when screening single drugs and preselected combinations

UNIQUE data and treatments for each patient’s as their own cancer cells are used for drug response analysis

VAST number of regimens are evaluated to maximize finding effective treatment, truly personalizing care

ALL actionable treatments within a drug set can be ranked based on sensitivity and compared, including against standard care

Biopharma Services

New target prioroitization

Large search discovery for new targets + combinations

combination discovery

Explore combination discovery for lead targets

biomarker identification

Find biomarker signatures based on phenotypic response curves

Dose Optimization

Retrospective or prospective studies to support dose optimization within trials

revive failed assets

Find new combination partners or companion Dx for assets that failed trials

Meet Our Team

Our ex vivo analytic platform, Optim.AI™, empowers oncologists to better guide treatment for patients with truly personalized results

Resources

Resources